Boyd Acquires Sensata’s Thermal Test and Controls Business
1.7.2022 18:29:00 EEST | Business Wire | Press release
Boyd, a world-leading innovator of technologies in engineered materials and thermal management, announced it acquired Sensata’s Thermal Test and Controls Business (NYSE:ST).
This business specializes in the design and manufacturing of advanced thermal control systems, adapters, and sockets critical to the thermal test process for high-end logic and memory semiconductors. With a long history of serving leading global semiconductor companies, the addition complements Boyd’s existing thermal business, which includes air and liquid cooled thermal management technologies.
Boyd designs and manufactures complex thermal solutions for high-performance semiconductors used in applications such as 5G, hyperscale data center, eMobility, and artificial intelligence. With this acquisition, Boyd expands its offering to current semiconductor customers by adding advanced controls and thermal test systems essential to the production of high-end memory and logic devices.
“This acquisition is a natural fit for Boyd and adds to our portfolio of thermal solutions for leading semiconductor companies,” said Boyd CEO Doug Britt. “The advanced technologists, material scientists, and solutions from Sensata’s Thermal Test and Controls Business broaden Boyd’s presence in the rapidly growing semiconductor industry.”
The acquired business will operate under the Boyd brand – which has delivered Trusted Innovation for nearly 100 years. We have closed our acquisition of the business, except for in Korea, which is pending customary regulatory approval.
About Boyd
Boyd is the trusted global innovator of sustainable solutions that make our customers’ products better, safer, faster, and more reliable. Our innovative engineered materials and thermal solutions advance our customers’ technology to maximize performance in 5G infrastructure and the world’s most advanced data centers; enhance reliability and extend range for electric and autonomous vehicles; advance the accuracy of cutting-edge personal healthcare and diagnostic systems; enable performance-critical aircraft and defense technologies; and accelerate innovation in next-generation electronics and human-machine-interface. Core to Boyd’s global manufacturing is a deep commitment to protect the environment with sustainable, scalable, lean, strategically located regional operations that reduce waste and minimize carbon footprint. We empower our employees, develop their potential, and inspire them to do the right things with integrity and accountability to champion our customers’ success.
Visit us at www.boydcorp.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220630005927/en/
Contact information
Amie Jeffries
Boyd
amie.jeffries@boydcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CAIRDAC Adds Operational Expertise to Its Board of Directors With the Appointment of Rinda Sama9.11.2026 14:44:00 EET | Press release
CAIRDAC, SA, a pre-revenue-stage medtech company developing ALPS™, a leadless, self-powered cardiac pacing system, today announced the appointment of Mr. Rinda Sama to its Board of Directors. His appointment adds deep manufacturing, quality and operational experience to the Board and follows the recent appointment of Raymond W. Cohen as Chairman. “Mr. Sama’s extensive experience in manufacturing, quality systems and operational scale-up for complex implantable devices will be extremely valuable to our Company as we prepare for clinical evaluation and the next stages of development,” said Edouard Fonck, Chief Executive Officer of CAIRDAC. Mr. Sama currently serves as CEO of Spiro Medical, a company focused on treating asthma employing a proprietary neuromodulation system. He previously served as Chief Operating Officer of publicly traded Axonics, Inc. where he was accountable for manufacturing and quality and the operational infrastructure that supported the company’s commercial growth.
Nominations Open for Sixth Edition of Aster Guardians Global Nursing Award 2027 Worth USD 250,000 Prize9.11.2026 14:35:00 EET | Press release
Aster DM Healthcare has announced the launch of the sixth edition of the Aster Guardians Global Nursing Award, inviting registered nurses worldwide to showcase their contributions to healthcare and compete for a prize of USD 250,000. The award recognises nurses whose work advances patient care, strengthens healthcare systems, drives innovation and transforms communities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109180902/en/ Aster Guardians Global Nursing Award - One nurse will win the trophy and the prize of USD 250,000 (Photo: AETOSWire) Open to registered nurses worldwide, the award recognises contributions across five areas: Patient Care, Nursing Education, Social and Community Service, Research and Innovation, and Nursing Leadership and Administration. Applicants can share their professional journeys through case-study questions, in multiple languages at www.asterguardians.com until December 31, 2026. The 2026
Datavault AI and Biochar Now Combine Insured Carbon Removal Credits with Patented Tokenization Technology9.11.2026 13:45:00 EET | Press release
Datavault AI Inc. (“Datavault” or the “Company”) (Nasdaq: DVLT), today announced a global strategic collaboration with Biochar Now to expand the distribution of verified, insured carbon removal credits through Datavault’s patented tokenization technology and global marketing and distribution capabilities. The partnership is designed to connect Biochar Now’s carbon removal credits with a broader network of buyers while strengthening transparency, traceability and accountability in the carbon markets. Under the agreement, Datavault AI will provide access to its carbon credit tokenization technology, including U.S. Patent No. 12,443,977 and related pending applications. It will also support worldwide demand generation, buyer development, marketing and distribution of eligible Biochar Now carbon credits, while also pursuing listings with existing and future partner exchange platforms. Biochar Now will pay Datavault AI for its technology and services; specific financial terms were not discl
NIQ to Present at 2026 J.P. Morgan Ultimate Services Investor Conference9.11.2026 13:45:00 EET | Press release
NielsenIQ (NYSE: NIQ) (the “Company”, or “NIQ”), a leading global consumer intelligence company, today announced that Jim Peck, Chairman and CEO, and Mike Burwell, CFO will participate in a fireside chat at the J.P. Morgan Ultimate Services Investor Conference on Tuesday, November 17, 2026 at 2:40 pm ET. A live webcast will be available on the NIQ investor relations website at https://investors.nielseniq.com. A replay will also be available on the Company's website following the conclusion of the presentation. About NielsenIQ NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior. Combining an unmatched global data footprint, granular consumer and retail measurement, and decades of AI modeling expertise, NIQ helps companies turn complex data into confident action. With operations in more than 90 countries covering approximately 82% of the world’s population and more than $7.4 trillion in consumer spend, N
Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression9.11.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the Company completed its submission of a New Drug Application (NDA) to the U.S. FDA for COMP360 psilocybin, its investigational synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). "People living with treatment-resistant depression have gone too long experiencing disproportionate suffering, despite years of trying available treatment options without meaningful relief. The completion of our NDA submission reflects years of perseverance and commitment by patients, families, advocates, researchers and healthcare providers who have worked alongside us toward the shared goal of bringing new treatment options to this community,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “Compass is leading the development of this new class of medicines with rigor and discipline, successfully
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
